General Information of Drug (ID: DMST5HF)

Drug Name
Nofazinlimab
Synonyms EQ176; CS1003
Indication
Disease Entry ICD 11 Status REF
Liver cancer 2C12 Phase 3 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DX9GT7

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Liver cancer
ICD Disease Classification 2C12
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04194775) A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC). U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of EQRx